Soligenix price to sales ratio SNGX

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 79.3×; Aug 2025
10-year median: 12.5×
10-year range: 1.1× to 79.3×
Peer median: 0.9×

Soligenix's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2025, at 79.3×.

On the days it had one over the last ten years, its median was 12.5×, from 1.1× in Jun 2017 to 79.3× in Aug 2025.

Price to sales ratio over time

median 12.5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	79.3×	15.8×	79.3×
2024	19.9×	3.0×	24.4×
2023	8.2×	2.4×	25.2×
2022	22.8×	20.7×	45.1×
2021	32.6×	15.1×	44.3×
2020	14.0×	6.0×	29.4×
2019	5.9×	2.4×	5.9×
2018	2.8×	2.8×	6.1×
2017	1.1×	1.1×	2.2×
2016	n/m a value too high to mean anything
2015	6.0×	3.4×	7.3×
2014	3.4×	3.2×	6.4×

Against its peers

Companies in Drug Manufacturers - General nearest Soligenix's size, closest first, today.

Company	Price to sales ratio
SNGXSoligenix	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Soligenix

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.